Le Lézard
Classified in: Health, Business
Subjects: CON, WOM, DEI

C-RAD and Accuray Sign Agreement to Enhance Radixact® System Breast Cancer Treatment Capabilities


UPPSALA, Sweden, and SUNNYVALE, Calif., Oct. 4, 2021 /PRNewswire/ -- C-RAD AB (NASDAQ Stockholm: CRAD B) and Accuray Incorporated (NASDAQ: ARAY) announced today they have signed an agreement designed to enhance the Accuray Radixact® System's ability to treat breast cancer. The companies will partner to provide customers with a solution for deep inspiration breath hold (DIBH)* using the C-RAD Catalyst+ HD and Radixact System. DIBH is a technique frequently used for breast cancer treatments. The development work will commence before the end of 2021 with the first interface linking the Catalyst technology and the Radixact System anticipated to be made available in mid-2022.

The Accuray Radixact System, the next generation TomoTherapy® platform, provides a fast, non-invasive, highly accurate and personalized option for the treatment of breast cancer. The system's helical design enables the delivery of radiation from 360 degrees around the patient, providing greater control of the radiation dose so it conforms precisely to the tumor and minimizes dose to healthy tissue. Radixact delivered radiation therapy may be an option for treating breast cancer at almost every stage and can be used in combination with surgery or chemotherapy. It is commonly used to help reduce the risk of breast cancer recurrence and/or to provide relief from symptoms, such as pain, associated with advanced disease.

The C-RAD Catalyst+ HD offers a complete solution for high precision patient positioning, intra-fraction motion management, and respiratory gating, ensuring the best possible treatment outcome for conventional and stereotactic radiation treatment delivery, including for breast cancers. In the modern era of radiation oncology where precision is crucial, the Catalyst+ HD is the precise answer to stereotactic radiation therapy.

"We are very pleased to partner up with Accuray and to develop this solution. This is another step towards our goal to make surface tracking standard of care. It is our firm belief that eventually a majority of the linacs in advanced radiation therapy markets will be equipped with surface tracking," says Tim Thurn, CEO and President at C-RAD AB, "Workflow and operational efficiency are key criteria for customers to choose their treatment system."

"We are excited to enter into this partnership with C-RAD, a company like ours, that is dedicated to providing radiation therapy solutions that enable clinicians to improve the lives of as many of their patients as possible," said Joshua H. Levine, chief executive officer of Accuray. "DIBH is a valuable approach for some patients with breast cancer undergoing radiation treatments. The combination of the Catalyst+ HD with the Radixact System is designed to make it easier for clinicians to leverage the advantages of our combined innovative solutions to effectively address the full range of breast cancer tumors they see in their daily practices."

*Works in progress. DIBH availability is pending development and regulatory clearance or approval.

About C-RAD
C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD (Shanghai) Medical Devices Co Ltd. In China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are integrated. C-RAD AB is listed on NASDAQ Stockholm. For more information on C-RAD, please visit http://www.c-rad.com.

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases?while making commonly treatable cases even easier?to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter, and YouTube.

For further information about C-RAD AB:
Tim Thurn
CEO C-RAD AB
Phone +46-18-666930
Email: investors@c-rad.com

For further information about Accuray Incorporated:
Beth Kaplan
Public Relations Director, Accuray
Phone +1 (408) 789-4426
Email: bkaplan@accuray.com

SOURCE Accuray Incorporated


These press releases may also interest you

at 18:54
EMP Metals Corp. ("EMP Metals" or the "Company") announces that it has entered into an advertising and investor awareness campaign agreement (the "Agreement") with Dig Media Inc. dba Investing News Network ("INN"). INN is a private company...

at 18:44
Androvett Legal Media & Marketing is proud to announce the additions of Kaylee Brock as Digital Project Manager and Nichole Brandt as Marketing Manager to the Dallas office....

at 18:40
People's Bank of Commerce announced today its financial results for the 4th quarter and year-ended 2021. Highlights Fourth quarter net income of $3.0 million, or $0.59 per diluted share Year-to-date net income of $11.5 million, or $2.44 per...

at 18:00
Community Healthcare Trust Incorporated  today announced that on Tuesday evening, February 15, 2022, after the market closes, it will report results for the fourth quarter of 2021.  On February 16, 2022, at 9:00 a.m. Central Time, Community...

at 17:43
Supermax Healthcare Canada wishes to clarify the circumstances and facts surrounding the decision, made with the Canadian government, to terminate the two contracts for the supply of nitrile gloves. At the outset, it is important to specify that the...

at 17:40
Further to disclosure requirements of applicable securities laws, Mitchell Goldhar is issuing this news release to disclose recent changes in his holdings of securities of SmartCentres Real Estate Investment Trust (the "REIT"). As of the date hereof,...



News published on 4 october 2021 at 07:00 and distributed by: